代谢功能障碍相关脂肪性肝炎临床试验的入组:筛选失败率的汇总分析
该汇总分析检索了PubMed和Cochrane图书馆,纳入67项成人MASH药物治疗的2期及以上随机对照试验,其中58项报告了入组数据。汇总筛选失败率为56.28%(95%CI 50.14-62.23),共涉及44,949人。最常见的筛选失败原因是受试者不符合入选标准,且筛选失败率在较近期试验、全球性试验和制药公司资助的试验中更高。
要点
- MASH随机对照试验的汇总筛选失败率为56.28%(95%CI 50.14-62.23),共纳入44,949人。
- 筛选失败最常见的原因是受试者不符合入选标准。
- 筛选失败率在较近期试验、全球性试验和制药公司资助的试验中更高;荟萃回归显示筛选失败率随时间推移和试验中心数量增加而上升。
核心结论
- 迫切需要基于证据的策略来降低MASH临床试验中较高的筛选失败率。
研究设计与样本
- 汇总分析,检索PubMed和Cochrane图书馆数据库,纳入67项成人MASH药物治疗的2期及以上随机对照试验(采用组织学入选标准),其中58项报告了入组数据。
主要发现
- 汇总筛选失败率为56.28%(95%CI 50.14-62.23),共涉及44,949人。
- 最常见的筛选失败原因是受试者不符合入选标准。
- 筛选失败率在较近期试验、全球性试验和制药公司资助的试验中更高。
- 荟萃回归显示筛选失败率随时间推移和试验中心数量增加而上升。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Screen failure is a major challenge in the enrollment of metabolic dysfunction-associated steatohepatitis (MASH) randomized controlled trials (RCTs), but its impact has not been systematically assessed. METHODS: We searched PubMed and the Cochrane Library databases for phase ≥2 RCTs of MASH pharmacotherapies in adults using histological inclusion criteria. Screen failure rates (SFRs) were pooled using a generalized linear mixed model. RESULTS: Of 67 included RCTs, 58 reported enrollment data. The pooled SFR was 56.28% (95% confidence interval 50.14-62.23) in 44,949 individuals. The most common reason for screen failure was ineligibility. SFR was higher in more recent trials, globally conducted trials, and trials funded by pharmaceutical companies. Meta-regressions showed an increase in SFR over time and with more trial sites. DISCUSSION: Evidence-based strategies to reduce the high SFR in MASH clinical trials are urgently needed.
引用
- Souza M, Al-Sharif L, Diaz I, et al. Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates. Am J Gastroenterol. 2025. PMID: 40323026. doi:10.14309/ajg.0000000000003520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。